Cargando…

Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy

Atherosclerosis with associated cardiovascular diseases remains one of the main causes of disability and death worldwide, requiring development of new solutions for prevention and treatment. Macrophages are the key effectors of a series of events involved in atherogenesis, such as inflammation, plaq...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakirov, Felix H., Zhang, Dongwei, Grechko, Andrey V., Wu, Wei‐Kai, Poznyak, Anastasia V., Orekhov, Alexander N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111069/
https://www.ncbi.nlm.nih.gov/pubmed/32237116
http://dx.doi.org/10.1002/prp2.584
_version_ 1783513198290272256
author Zakirov, Felix H.
Zhang, Dongwei
Grechko, Andrey V.
Wu, Wei‐Kai
Poznyak, Anastasia V.
Orekhov, Alexander N.
author_facet Zakirov, Felix H.
Zhang, Dongwei
Grechko, Andrey V.
Wu, Wei‐Kai
Poznyak, Anastasia V.
Orekhov, Alexander N.
author_sort Zakirov, Felix H.
collection PubMed
description Atherosclerosis with associated cardiovascular diseases remains one of the main causes of disability and death worldwide, requiring development of new solutions for prevention and treatment. Macrophages are the key effectors of a series of events involved in atherogenesis, such as inflammation, plaque formation, and changes in lipid metabolism. Some of these events were shown to be associated with mitochondrial dysfunction and excessive mitochondrial DNA (mtDNA) damage. Moreover, macrophages represent a promising target for novel therapeutic approaches that are based on the expression of various receptors and nanoparticle uptake. Lipid‐based gene delivery to mitochondria is considered to be an interesting strategy for mtDNA damage correction. To date, several nanocarriers and their modifications have been developed that demonstrate high transfection efficiency and low cytotoxicity. This review discusses the possibilities of lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy.
format Online
Article
Text
id pubmed-7111069
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71110692020-04-02 Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy Zakirov, Felix H. Zhang, Dongwei Grechko, Andrey V. Wu, Wei‐Kai Poznyak, Anastasia V. Orekhov, Alexander N. Pharmacol Res Perspect Reviews Atherosclerosis with associated cardiovascular diseases remains one of the main causes of disability and death worldwide, requiring development of new solutions for prevention and treatment. Macrophages are the key effectors of a series of events involved in atherogenesis, such as inflammation, plaque formation, and changes in lipid metabolism. Some of these events were shown to be associated with mitochondrial dysfunction and excessive mitochondrial DNA (mtDNA) damage. Moreover, macrophages represent a promising target for novel therapeutic approaches that are based on the expression of various receptors and nanoparticle uptake. Lipid‐based gene delivery to mitochondria is considered to be an interesting strategy for mtDNA damage correction. To date, several nanocarriers and their modifications have been developed that demonstrate high transfection efficiency and low cytotoxicity. This review discusses the possibilities of lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy. John Wiley and Sons Inc. 2020-04-01 /pmc/articles/PMC7111069/ /pubmed/32237116 http://dx.doi.org/10.1002/prp2.584 Text en © 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Zakirov, Felix H.
Zhang, Dongwei
Grechko, Andrey V.
Wu, Wei‐Kai
Poznyak, Anastasia V.
Orekhov, Alexander N.
Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy
title Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy
title_full Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy
title_fullStr Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy
title_full_unstemmed Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy
title_short Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy
title_sort lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111069/
https://www.ncbi.nlm.nih.gov/pubmed/32237116
http://dx.doi.org/10.1002/prp2.584
work_keys_str_mv AT zakirovfelixh lipidbasedgenedeliverytomacrophagemitochondriaforatherosclerosistherapy
AT zhangdongwei lipidbasedgenedeliverytomacrophagemitochondriaforatherosclerosistherapy
AT grechkoandreyv lipidbasedgenedeliverytomacrophagemitochondriaforatherosclerosistherapy
AT wuweikai lipidbasedgenedeliverytomacrophagemitochondriaforatherosclerosistherapy
AT poznyakanastasiav lipidbasedgenedeliverytomacrophagemitochondriaforatherosclerosistherapy
AT orekhovalexandern lipidbasedgenedeliverytomacrophagemitochondriaforatherosclerosistherapy